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Case report
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Summary:
We report a patient with multiple myeloma who suf-
fered from hyperammonemia after a second stem cell
autograft. This syndrome is not well known but is asso-
ciated with a high mortality rate. Considering the possi-
bility of this diagnosis in patients developing confusion
and neurological degradation with respiratory alkalosis
after intensive chemotherapy, could allow earlier treat-
ment and perhaps improved survival. Possible mech-
anisms and potential therapies are discussed. With
rapid recognition and treatment of the syndrome, the
patient fully recovered. One and a half years later,
she is still alive and well, on interferon for persisting
myeloma. Bone Marrow Transplantation (2000) 26, 343–
345.
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A 62-year-old Caucasian woman was a heavy smoker suf-
fering from emphysema and ischemic cardiopathy. In Feb-
ruary 1996, a diagnosis of IgA lambda multiple myeloma
was made (IgA 29 g/l, Bence–Jones negative, multiple bone
lesions on clavicles and skull). She was classified as stage
IIIA according to the Durie and Salmon classification. She
received seven courses of VMCP (vincristine, cyclophos-
phamide, melphalan and prednisolone) without a good
response. Consequently, she was treated with four cycles
of VAD (vincristine, doxorubicine, dexamethasone) fol-
lowed by mobilization chemotherapy with cyclophospham-
ide plus etoposide to collect peripheral blood stem cells
(PBSC) for two autotransplants. Before transplantation, she
was in partial response (.50%). A first stem cell autograft
was carried out in March 1997 after melphalan 200 mg/m2
without any significant complication. She entered complete
remission. Despite this, a relapse was observed 9 months
later.
A second transplant was thus undertaken in February
1998. Conditioning consisted of TBI (6 · 2 Gy) and mel-
Correspondence: Dr Y Beguin, University of Lie`ge, Department of
Hematology, CHU Sart-Tilman, 4000 Lie`ge, Belgium
Received 4 January 2000; accepted 16 April 2000
phalan (140 mg/m2). On day 5, the patient developed fever
and dyspnea with bronchospasm. Broad-spectrum anti-
biotics including teicoplanine, imipenem, gentamicin and
amphotericin B were unsuccessful. Several blood cultures
yielded Candida famata and a chest CT-scan showed dis-
seminated micronodules. 5-Fluorocytosine was started in
addition to amphotericin B and the central catheter was
removed. Two days later, blood cultures became negative,
fever disappeared and the CRP returned to normal. Simul-
taneously, the patient developed mental confusion with res-
piratory alkalosis, which prompted her admission to an
intensive care unit where tracheal intubation was necessary.
A cerebral CT-scan did not explain the confusion but
an electroencephalogram showed a pattern compatible with
metabolic encephalopathy. Arterial plasma ammonia con-
centrations were measured and revealed very high levels,
ie .120 mmol/l (N , 40 mg/l). There was neither alter-
ation of liver function nor other metabolic disturbances. A
lumbar puncture showed an increase of glutamine and
ammonia (102 mmol/l). Orotic acid was undetectable in the
urine. A liver biopsy was performed and confirmed our sus-
picion of idiopathic hyperammonemia by showing
microvesicular steatosis. Parenteral alimentation was
discontinued to lower protein intake and treatment with
lactulose, omeprazole and metronidazole was started.
Additionally, we used carnitine (50 mg/kg/day) to promote
urea production. Because a test dose of flumazenil, an
antagonist of endogenous benzodiazepines, induced a spec-
tacular awakening of the patient, she was also given a
continuous infusion of the drug.
The patient was extubated on day 18 and treatment was
continued until complete resolution of cerebral symptoms
on day 35. She was discharged from hospital on day 43.
She remained well afterwards without further therapy. Her
multiple myeloma entered excellent partial remission
(.90%). Maintenance treatment with interferon was started
on day 180 but she showed evidence of moderate myeloma
progression 1 year after the second transplant although no
other treatment has been required so far apart from inter-
feron maintenance. With a follow-up of 1. years, she has
remained well neurologically.
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Idiopathic hyperammonemia syndrome has been previously
described in BMT patients with an incidence as high as
0.5 to 1%.1,2 It is defined as an elevated plasma ammonia
concentration in the absence of significant liver function
abnormalities. This syndrome has been described in
patients receiving intensive chemotherapy for hematolog-
ical malignancies (ALL, AML, CMML, MM) as well as
after autologous or allogenic BMT or PBSCT (about 20
cases described).1,2 Many cytoreductive drugs have been
incriminated besides asparaginase or valproic acid which
are known to produce hyperammonemia.1,3 It usually
occurs between 15 and 100 days after transplant when fever
and neutropenia are present.2 Our patient had a particularly
early occurrence on day 5. Several explanations have been
proposed for its more frequent incidence in leukopenic and
febrile patients after chemotherapy.4 First, severe infections
during myelosuppression increase ammonia production via
urease or other ammonia-generating enzymes. Second, mer-
captans and short-chain fatty acids decrease the ability to
create urea from ammonia in the liver. Finally, GI bleeding
may also increase ammonia production and leukemic cells
themselves could contribute to that production.
The syndrome has a rather atypic presentation, thus often
resulting in a delayed diagnosis because there are many
other possible causes (toxic, tumoral, infectious, metabolic
or hemorrhagic) of confusion in immunosuppressed
patients after chemotherapy for hematological malig-
nancies. The principal manifestations are neurological with
confusion, lethargy, cerebellar dysfunction that can evolve
into seizures, encephalopathy and coma.2,4–6 All patients
have evidence of raised intracranial pressure but the exact
mechanism is not known.6 It could be a direct toxic effect
of ammonia on intracranial blood vessels causing astrocyte
swelling. Alternatively, it could be due to changes in cer-
ebral metabolism by interference with cerebral respiration
or accumulation of neurotransmitter substances, depletion
of high-energy phosphates or change in cellular pH.
Another possibility could be the accumulation of intracellu-
lar glutamine as described later.
These symptoms are accompanied by hyperventilation
and respiratory alkalosis. The syndrome resembles Reye’s
syndrome or inherited defects of urea synthesis.7 However,
plasma amino acid and urinary orotic acid levels when mea-
sured did not show any argument for congenital urea cycle
defects. Liver function tests are most often normal or only
modestly abnormal.2,4 Prothrombin time is normal.2 Plasma
and CSF ammonia levels are increased by definition.
Arterial blood gases show respiratory alkalosis due to
hyperventilation.
Neurologically, autopsies reveal astrocyte swelling and
often herniation of cerebellar tonsils.4 The white matter is
often vacuolated.8 These observations are in agreement
with the fact that cerebral edema is a consequence of hyper-
ammonemia.2,9,10 Indeed, the cause of astrocyte edema is
unknown but it could reflect the osmotic effect of accumu-
lated intracellular glutamine which is the primary metabolic
product of ammonia metabolism in the brain.1 Glutamine
synthetase, which is responsible for this, is located in astro-
cytes. Glutamine concentration is raised in the brain and
cerebrospinal fluid in cases of idiopathic hyperammonemia
and its level is associated with mental confusion as was the
case with our patient. The liver may show centrilobular
fatty infiltration, bile stasis and passive congestion.11 The
liver biopsy in our patient disclosed typical microvesicular
steatosis. This differs from Reye’s syndrome where the
mitochondria appear abnormal. Finally, it is noteworthy to
mention that a number of patients have GI bleeding demon-
strated either clinically or at autopsy.2
Treatment of the syndrome first requires elimination of
dietary nitrogen and suppression of intestinal ureolysis by
lactulose and neomycin. Energy should be provided by
concentrated glucose to minimize endogenous protein
catabolism.2,4 Tracheal intubation is often necessary for
management of respiratory alkalosis.2 This would allow
creation of a pH gradient between blood and brain because
at physiological pH, NH3 is ionized to NH4+ which is rela-
tively lipid insoluble.1 Dialysis is also effective for reduc-
ing ammonia concentration, but part of its beneficial effect
may reside in the removal of urea precursors.6 By analogy
with congenital urea-cycle deficit, ammonia-trapping
therapy has been used. Indeed, sodium benzoate or phenyl-
acetate react with glutamine and glycine to form phenyl-
acetyl-glutamine and hippurate which are excreted in the
urine at a rate that approximates renal blood flow.12 These
metabolites are also cleared by hemodialysis.11,13 Thus,
ammonia production is decreased by diverting precursors.1
As in our patient, l-carnitine can also be used because its
administration prevents the neurological symptoms of acute
ammonia toxicity by improving mitochondrial respiration
and favoring ureagenesis.14,15 Continuous infusion of flu-
mazenil could also be recommended.16 This drug is in fact
an antagonist of benzodiazepine receptors and therefore
could prevent the effect of endogenous benzodiazepines
that are partly responsible for hepatic encephalopathy.
Indeed, neurologic impairment in hepatic encephalopathy
is commonly attributed to GABA-aminobutyric acid, the
principal inhibitory neurotransmitter of the mammalian
brain.17 GABA is synthesized by gut bacteria and can
induce an augmentation of the number of its own receptors
in the brain. Furthermore, the receptor for benzodiazepines
is one component of the GABA postsynaptic receptor. Sev-
eral studies have shown clinical and electrophysiological
improvement of hepatic encephalopathy by infusion of
benzodiazepine receptor antagonists like flumazenil.16,18,19
This suggests the existence of an endogenous ligand with
benzodiazepine agonist-like properties but this has never
been clearly demonstrated until now.18 The mortality asso-
ciated with the syndrome is over 50% despite appropriate
therapy. It is very important to recognize the disorder very
quickly to be able to start effective conservative manage-
ment. With this strategy, it is possible to obtain complete
and durable resolution of the syndrome.
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